Safety and effects of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes

被引：0
|
作者：
Maggs, D.
MacConell, L.
Zhuang, D.
Schnabel, C.
Taylor, K.
Trautmann, M.
Kim, D.
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
[2] Lilly Forsch GmbH, Hamburg, Germany
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0002
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, Andrew
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Annett, Miriam
    Aroda, Vanita
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [22] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, A.
    Capehom, M.
    Charpentier, G.
    Dotta, E.
    Henkel, E.
    Lingvay, I.
    Holst, A. Gaarsdal
    Annett, M.
    Aroda, V.
    DIABETOLOGIA, 2016, 59 : S76 - S76
  • [23] Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
    Deng, Wuquan
    Qiu, Sheng
    Yang, Gangyi
    Chen, Bing
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1153 - 1162
  • [24] Safety and efficacy of once monthly exenatide administration over 20 weeks in patients with type 2 diabetes
    MacConell, L.
    Malloy, J.
    Huang, W.
    Cirincione, B.
    Shen, L.
    Porter, L.
    DIABETOLOGIA, 2011, 54 : S38 - S38
  • [25] Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
    Mann, Katherine V.
    Raskin, Philip
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 229 - 239
  • [26] Exenatide Once Weekly Elicited Improvements in Blood Pressure and Lipid Profile Over 52 Weeks in Patients with Type 2 Diabetes
    Bergenstal, Richard M.
    Kim, Terri
    Trautmann, Michael
    Zhuang, Dongliang
    Okerson, Ted
    Taylor, Kristin
    CIRCULATION, 2008, 118 (18) : S1086 - S1086
  • [27] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
    Tan, Xueying
    Cao, Xiaojing
    Zhou, Minzhi
    Zou, Ping
    Hu, Jingbo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1083 - 1089
  • [28] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
    Iwamoto, Kazuya
    Nasu, Risa
    Yamamura, Ayuko
    Kothare, Prajakti A.
    Mace, Kenneth
    Wolka, Anne M.
    Linnebjerg, Helle
    ENDOCRINE JOURNAL, 2009, 56 (08) : 951 - 962
  • [29] Safety and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes: An Integrated Analysis of 4328 Patients
    Macconell, Leigh
    Gurney, Kate
    Malloy, Jaret
    Zhang, H.
    Zhou, Ming
    Chen, Steve
    DIABETES, 2012, 61 : A598 - A598
  • [30] Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
    Biftu, Tesfaye
    Sinha-Roy, Ranabir
    Chen, Ping
    Qian, Xiaoxia
    Feng, Dennis
    Kuethe, Jeffrey T.
    Scapin, Giovanna
    Gao, Ying Duo
    Tan, Youwei
    Krueger, Davida
    Bak, Annette
    Eiermann, George
    He, Jiafang
    Cox, Jason
    Hicks, Jacqueline
    Lyons, Kathy
    He, Huaibing
    Salituro, Gino
    Tong, Sharon
    Patel, Sangita
    Doss, George
    Petrov, Aleksandr
    Wu, Joseph
    Xu, Shiyao Sherrie
    Sewall, Charles
    Zhang, Xiaoping
    Zhang, Bei
    Thornberry, Nancy A.
    Weber, Ann E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (08) : 3205 - 3212
12345